Company: PSTV
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047698
Chunk: 165

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 8
Chunk 165
---
 year from the date of the purchase. 

 5.       Loss per Share The  shares of the Company's common stock underlying the pre-funded warrants described in Note 15, are included in the weighted average outstanding common stock in the calculation of basic and diluted net loss per share. The Company considers Series A Warrants, and Series B Warrants to be participating securities, because holders of such instruments participate in the event a dividend is paid on common stock. The holders of the Series A Warrants and Series B Warrants do not have a contractual obligation to share in the Company’s losses. As such, losses are attributed entirely to common stockholders.  The following table sets forth the computation of basic and diluted net loss per share of common stock for the periods indicated, in thousands except share and per share data: 

86

        For the Year Ended December 31,

        2024

        2023

        Basic and diluted net loss per share of common stock calculation:

        Net loss
         
        $
        (12,978
        )
         
        $
        (13,316
        )

        Change in fair value of warrants

        (5,047
        )

        -

        Net loss attributable to common stockholders - diluted
         
        $
        (18,025
        )
         
        $
        (13,316
        )

        Weighted average shares of common stock outstanding - basic

        6,640,251

        3,140,925

        Net loss per share of common stock - basic
         
        $
        (1.95
        )
         
        $
        (4.24
        )

        Weighted average shares of common stock - diluted

        7,700,774

        3,140,925

        Net loss per share of common stock - diluted
         
        $
        (2.34
        )
         
        $
        (4.24
        )
       
       The following were excluded from the diluted loss per share calculation for the periods presented because their effect would be anti-dilutive: 

        For the Year Ended December 31,

        2024

        2023

        Outstanding stock options

        598,540

        140,109

        Preferred stock

        28,190

        28,190

        Outstanding warrants

        7,183,064

        142,733

        Total